Published: Fri, November 15, 2019
Health Care | By Cedric Leonard

European Union approves Ebola vaccine for commercial use

European Union approves Ebola vaccine for commercial use

It was in 2014 that Merck bought the rights to develop the vaccine, following the Ebola outbreak in West Africa. "We at Merck are honored to participate in a aspect in Ebola outbreak response endeavours and we continue to be dedicated to our associates and the people we provide".

It will be extremely helpful for curbing the ongoing Ebola outbreak in the Democratic Republic of Congo.

The current outbreak is the second-largest recorded, in 2014, virus killed than 11,000 people in West Africa. Moreover, the first batch of 500,000 doses of J&J's Ebola vaccine will be inoculated tomorrow Thursday in Goma to complement Merck's.

Director-General Dr Tedros Adhanom Ghebreyesus in a statement said the agency had prequalified Merck's Ebola vaccine that had already saved many lives in the DR Congo Ebola outbreak, where more than 2,36,000 people have been vaccinated with rVSV ZEBOV GP donated by USA drugmaker Merck & Co Inc to the agency, and the decision by European regulator would help it to eventually save many more.

"We also look forward to continuing to work with the FDA and the African countries on their regulatory reviews over the coming months and with the World Health Organization on vaccine prequalification, which will help broaden access to this important vaccine for those who need it most".

The current-day outbreak within the DRC has killed almost 2,200 contemplating that August 2018, resulting in almost three, 300 conditions.

Tiny deer-like species spotted for first time in decades
The scientists then set up three camera traps, which in five months captured 275 photos of the silver-backed chevrotain. Despite the name, they are neither mice nor deer but the world's smallest ungulate, or hoofed animal.


"Getting a vaccine as quickly as doable from this bad virus has been a precedence for the global local community ever considering that Ebola hit West Africa 5 yrs back", European Commissioner Vytenis Andriukaitis claimed in a press release Sunday, November 10.

The US Foodstuff and Drug Administration is predicted to make an approval ultimate choice on the vaccine in March 2020.

The vaccine was initially developed by researchers at the Public Health Agency of Canada's National Microbiology Laboratory, which subsequently licensed it to NewLink Genetics Corporation.

In an announcement, the World Health Organization noted that it was "the fastest vaccine prequalification process ever conducted by WHO" and came less than 48 hours after the European Commission approved the vaccine.

The vaccine, called ERVEBO, can be marketed in the 28 countries that are members of the European Union, as well as European Economic Area members, Iceland, Liechtenstein, and Norway. Merck's V920 vaccine supply replenishment activities are supported by partial Federal funding from BARDA under Contract No. HHSO100201700012C. "It is a historic milestone and a testament to the power of science, innovation and public-private partnership", Kenneth Frazier, chairman and chief executive officer at Merck, said.

Like this: